Full Evidence Report on the R21/Matrix-M Malaria Vaccine

In October 2021, WHO recommended the first malaria vaccine, RTS,S/AS01, for the prevention of Plasmodium falciparum (P. falciparum) malaria in children living in regions with moderate to high transmission, as defined by WHO. The vaccine can be given as a 3-dose primary schedule with a later fourth dose to prolong duration of protection. In areas of highly seasonal malaria or perennial malaria transmission with seasonal peaks, countries may consider providing the vaccine in a 5-dose strategy seasonally, just prior to the peak transmission season, to increase impact.